Key facts
- Kangaroo Biomedical’s last known valuation is $14.0M (Nov 2025).
- It has raised $4.5M; the latest was Seed Round ($4.5M) in Nov 2025.
- Notable investors include Draper Associates, VU Venture Partners, ZAKA VC, 2b AHEAD Ventures, Immortal Dragons.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Kangaroo Biomedical
- ·The full record, as it builds
Funding rounds
No funding rounds for Kangaroo Biomedical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kangaroo Biomedical
Operator of a biotechnology company intended to focus on women's reproductive health. The company develops advanced cell-based technologies aimed at enhancing fertility treatments, particularly in areas such as in-vitro fertilization (IVF), egg freezing, and ovarian health, utilizing stem-cell-derived ovarian support cells, enabling the healthcare industry to address unmet medical needs across the female reproductive lifespan.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2023
- Website
- kangaroobiomedical.com/
- Ownership
- Privately Held (backing)
Kangaroo Biomedical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kangaroo Biomedical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kangaroo Biomedical in its N-PORT filings yet. We sweep new filings monthly.